{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T12:07:13Z","timestamp":1795176433339,"version":"4.10.3"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Antiplatelet agents are critical for preventing cardiovascular events. However, these therapies are associated with potentially fatal bleeding risks. This study aimed to comprehensively analyze bleeding events associated with antiplatelet therapies over the past two decades and investigate the role of pharmacist-led interventions in mitigating these risks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data were extracted from the FDA Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database, both spanning reports from 2004 to 2024. Signal detection was performed using four algorithms: reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and empirical Bayes geometric mean. The analysis included temporal trends, indication distribution, time-to-onset, and outcomes of bleeding events. Additionally, the impact of combined drug use on bleeding risk was assessed. The impact of pharmacists in antiplatelet medication management was reviewed, focusing on interventions and their effectiveness in clinical settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 22\u00a0546 bleeding event reports were identified in FAERS and 8916 in JADER. The analysis revealed significant signals for various bleeding adverse events, with the highest signal strength observed for rare events such as hemorrhagic thyroid cyst, spinal subarachnoid hemorrhage, and hemorrhagic adrenal infarction in FAERS, while the three highest signal strengths were Heyde\u2019s syndrome, habitual abortion, and thyroid hemorrhage in JADER. The analysis revealed that older adults aged 65 or older and patients requiring hospitalization were disproportionately affected. The combined use of antiplatelet drugs with non-steroidal anti-inflammatory drugs, anticoagulants, and other drug classes significantly increased bleeding risk. The time-to-onset analysis showed that bleeding events could occur at any time during antiplatelet therapy, highlighting the need for continuous monitoring. Pharmacist-led interventions were reviewed and found to be effective in reducing bleeding complications and improving patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study provides robust evidence of the bleeding risks associated with antiplatelet therapies across diverse clinical settings, emphasizing the need for heightened clinical vigilance. Furthermore, it highlights the critical role of pharmacists in optimizing antiplatelet therapy management and reducing bleeding complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000003667","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:00:09Z","timestamp":1761577209000},"page":"3612-3624","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Bleeding and antiplatelet therapies: a combined pharmacovigilance analysis of the FDA Adverse Event Reporting System and Japanese Adverse Drug Event Report databases, and the role of pharmacists"],"prefix":"10.1097","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2511-0156","authenticated-orcid":false,"given":"Liu-Cheng","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2624-9923","authenticated-orcid":false,"given":"Zhi-Hui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Vascular Anomalies, Shanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Department of Endocrinology, Nanxiang Branch of Ruijin Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2398-4025","authenticated-orcid":false,"given":"Miao-Miao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9691-0328","authenticated-orcid":false,"given":"Feng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ningbo No.2 Hospital, Ningbo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1556-4365","authenticated-orcid":false,"given":"Kai-Li","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People\u2019s Hospital, Quzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"R1-20260512","doi-asserted-by":"crossref","first-page":"6167\u201378","DOI":"10.2147\/JIR.S439205","article-title":"Recent advances on the molecular mechanism and clinical trials of venous thromboembolism","volume":"16","author":"Huang","year":"2023","journal-title":"J Inflamm Res"},{"key":"R2-20260512","doi-asserted-by":"crossref","first-page":"1643\u201355","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N Engl J Med"},{"key":"R3-20260512","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jvs.2023.05.031","article-title":"Mortality and morbidity following initiation of anticoagulant or antiplatelet treatment for blunt cerebrovascular injury","volume":"78","author":"Leverich","year":"2023","journal-title":"J Vasc Surg"},{"key":"R4-20260512","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.3390\/jcm9072064","article-title":"Acute coronary syndrome, antiplatelet therapy, and bleeding: a clinical perspective","volume":"9","author":"Tersalvi","year":"2020","journal-title":"J Clin Med"},{"key":"R5-20260512","doi-asserted-by":"crossref","first-page":"1342\u201348","DOI":"10.1016\/j.amjmed.2022.07.022","article-title":"Impact of bleeding on myocardial infarction, stroke, and death during 12 months dual antiplatelet therapy after acute coronary syndrome","volume":"135","author":"Serebruany","year":"2022","journal-title":"Am J Med"},{"key":"R6-20260512","doi-asserted-by":"crossref","first-page":"281","DOI":"10.31083\/j.rcm2508281","article-title":"Current antithrombotic treatments for cardiovascular diseases: a comprehensive review","volume":"25","author":"Galanti","year":"2024","journal-title":"Rev Cardiovasc Med"},{"key":"R7-20260512","doi-asserted-by":"crossref","first-page":"900114","DOI":"10.3389\/fendo.2022.900114","article-title":"Gaps of medication treatment management between guidelines and real-world for inpatients with type 2 diabetes in china from pharmacist\u2019s perspective","volume":"13","author":"Song","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R8-20260512","first-page":"291\u2013300","article-title":"Antiplatelet, anticoagulant or both? A tool for pharmacists","volume":"152","author":"Schmode","year":"2019","journal-title":"Can Pharm J (Ott)"},{"key":"R9-20260512","doi-asserted-by":"crossref","first-page":"973\u201390","DOI":"10.1002\/phar.1447","article-title":"Strategies to reduce bleeding risk in acute coronary syndromes and percutaneous coronary intervention: new and emerging pharmacotherapeutic considerations","volume":"34","author":"Coons","year":"2014","journal-title":"Pharmacotherapy"},{"key":"R10-20260512","doi-asserted-by":"crossref","first-page":"405\u201312","DOI":"10.1007\/s11239-020-02207-3","article-title":"Evaluation and optimization of prescribed concomitant antiplatelet and anticoagulation therapy centrally managed by an anticoagulation management service","volume":"51","author":"Zekery-Saad","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"R11-20260512","doi-asserted-by":"crossref","first-page":"986\u201392","DOI":"10.1136\/bmjqs-2015-004411","article-title":"SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process","volume":"25","author":"Ogrinc","year":"2016","journal-title":"BMJ Qual Saf"},{"key":"R12-20260512","first-page":"100082","article-title":"Transparency in the reporting of Artificial INtelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R13-20260512","first-page":"1074\u201393","article-title":"ASHP national survey of pharmacy practice in hospital settings: dispensing and administration-2020","volume":"78","author":"Pedersen","year":"2021","journal-title":"Am J Health Syst Pharm"},{"key":"R14-20260512","doi-asserted-by":"crossref","first-page":"1133662","DOI":"10.3389\/fcvm.2023.1133662","article-title":"Escitalopram-induced sinus bradycardia in coronary heart disease combined with depression: a case report and review of literature","volume":"10","author":"Li","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"R15-20260512","doi-asserted-by":"crossref","first-page":"326\u201336","DOI":"10.1002\/ddr.22025","article-title":"Treatment strategies and pharmacist-led medication management for Helicobacter pylori infection","volume":"84","author":"Wang","year":"2023","journal-title":"Drug Dev Res"},{"key":"R16-20260512","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40780-023-00296-9","article-title":"Significance of pharmacist intervention to oral antithrombotic therapy in the pharmaceutical outpatient clinic of cardiovascular internal medicine: a retrospective cohort study","volume":"9","author":"Kurimura","year":"2023","journal-title":"J Pharm Health Care Sci"},{"key":"R17-20260512","doi-asserted-by":"crossref","first-page":"985\u201395","DOI":"10.1007\/s11096-016-0329-y","article-title":"Decision-making around antithrombotics for stroke prevention in atrial fibrillation: the health professionals\u2019 views","volume":"38","author":"Wang","year":"2016","journal-title":"Int J Clin Pharm"},{"key":"R18-20260512","doi-asserted-by":"crossref","first-page":"2736\u201347","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"R19-20260512","doi-asserted-by":"crossref","first-page":"436\u201345","DOI":"10.1007\/s11239-021-02551-y","article-title":"Antithrombosis stewardship efforts to de-escalate inappropriate combined therapy in outpatient clinics","volume":"53","author":"Meador","year":"2022","journal-title":"J Thromb Thrombolysis"},{"key":"R20-20260512","doi-asserted-by":"crossref","first-page":"e0235048","DOI":"10.1371\/journal.pone.0235048","article-title":"Effect of antithrombotic stewardship on the efficacy and safety of antithrombotic therapy during and after hospitalization","volume":"15","author":"Dreijer","year":"2020","journal-title":"PLoS One"},{"key":"R21-20260512","doi-asserted-by":"crossref","first-page":"946415","DOI":"10.3389\/fphar.2022.946415","article-title":"Potential drug-drug interactions in drug therapy for older adults with chronic coronary syndrome at hospital discharge: a real-world study","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Pharmacol"},{"key":"R22-20260512","doi-asserted-by":"crossref","first-page":"3896\u2013902","DOI":"10.1111\/bcp.15288","article-title":"Prevalence and management of drug interactions between nonsteroidal anti-inflammatory drugs and antithrombotics in ambulatory care","volume":"88","author":"Mehuys","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"R23-20260512","doi-asserted-by":"crossref","first-page":"1194201","DOI":"10.3389\/fphar.2024.1194201","article-title":"Impact of a DSS-supported medication review on the safety of drug therapy and quality of life in patients with antithrombotic therapy","volume":"15","author":"Hassanzadeh","year":"2024","journal-title":"Front Pharmacol"},{"key":"R24-20260512","first-page":"598\u2013606","article-title":"Assessment of eptifibatide dosing in renal impairment before and after in-service education provided by pharmacists","volume":"13","author":"Donovan","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"R25-20260512","doi-asserted-by":"crossref","first-page":"e20142","DOI":"10.1097\/MD.0000000000020142","article-title":"Development of an application for management of drug holidays in perioperative periods","volume":"99","author":"Kimura","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R26-20260512","doi-asserted-by":"crossref","first-page":"e15380","DOI":"10.1111\/ctr.15380","article-title":"Anticoagulation and antiplatelet regimen in cardiac transplant. clinical characteristics, outcomes, and blood product transfusion","volume":"38","author":"Groba Marco","year":"2024","journal-title":"Clin Transplant"},{"key":"R27-20260512","doi-asserted-by":"crossref","first-page":"2686\u201399","DOI":"10.1111\/bcp.15221","article-title":"Antiplatelet therapy in cardiovascular disease: current status and future directions","volume":"88","author":"Passacquale","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"R28-20260512","doi-asserted-by":"crossref","first-page":"1527667","DOI":"10.3389\/fcvm.2025.1527667","article-title":"Antiplatelet strategy for patients with acute coronary syndrome and chronic kidney disease: a systematic review and meta-analysis","volume":"12","author":"Li","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"R29-20260512","doi-asserted-by":"crossref","first-page":"1412944","DOI":"10.3389\/fcvm.2024.1412944","article-title":"Safety and efficacy of aspirin and indobufen in the treatment of coronary heart disease: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"R30-20260512","doi-asserted-by":"crossref","first-page":"100619","DOI":"10.1016\/j.blre.2019.100619","article-title":"Management of bleeding and procedures in patients on antiplatelet therapy","volume":"39","author":"Swan","year":"2020","journal-title":"Blood Rev"},{"key":"R31-20260512","doi-asserted-by":"crossref","first-page":"1402672","DOI":"10.3389\/fcvm.2024.1402672","article-title":"Machine learning derived model for the prediction of bleeding in dual antiplatelet therapy patients","volume":"11","author":"Qian","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"R32-20260512","doi-asserted-by":"crossref","first-page":"307\u201313","DOI":"10.1111\/j.1472-8206.2010.00915.x","article-title":"Antiplatelet drugs in the elderly: prescriptions often inappropriate and reduced tolerance by associated diseases and drugs","volume":"26","author":"Cadiou","year":"2012","journal-title":"Fundam Clin Pharmacol"},{"key":"R33-20260512","first-page":"1509\u201318","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"R34-20260512","doi-asserted-by":"crossref","first-page":"423\u201327","DOI":"10.1111\/j.1365-2044.2007.05368.x","article-title":"Subarachnoid haematoma after spinal anaesthesia mimicking transient radicular irritation: a case report and review","volume":"63","author":"Lam","year":"2008","journal-title":"Anaesthesia"},{"key":"R35-20260512","first-page":"533\u201335","article-title":"Spinal subarachnoid haematoma after spinal anaesthesia: case report","volume":"66","author":"Vidal","year":"2016","journal-title":"Braz J Anesthesiol"},{"key":"R36-20260512","doi-asserted-by":"crossref","first-page":"e2449017","DOI":"10.1001\/jamanetworkopen.2024.49017","article-title":"Risk of intracranial hemorrhage associated with direct oral anticoagulation vs antiplatelet therapy: a systematic review and meta-analysis","volume":"7","author":"Coyle","year":"2024","journal-title":"JAMA Network Open"},{"key":"R37-20260512","first-page":"737\u201348","article-title":"Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low-dose rivaroxaban, or the combination: secondary analysis of the COMPASS randomised controlled trial","volume":"60","author":"Forbes","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"R38-20260512","doi-asserted-by":"crossref","first-page":"1835\u201343","DOI":"10.1503\/cmaj.100912","article-title":"Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction","volume":"183","author":"Labos","year":"2011","journal-title":"CMAJ"},{"key":"R39-20260512","doi-asserted-by":"crossref","first-page":"4094\u2013102","DOI":"10.1097\/JS9.0000000000002435","article-title":"Safety evaluation of inotuzumab ozogamicin: a pharmacovigilance study based on the FAERS database","volume":"111","author":"Duan","year":"2025","journal-title":"Int J Surg"},{"key":"R40-20260512","first-page":"1988\u201394","article-title":"Systematic analysis of sugammadex-related adverse drug reaction signals using FAERS database","volume":"111","author":"Liu","year":"2025","journal-title":"Int J Surg"},{"key":"R41-20260512","doi-asserted-by":"crossref","first-page":"360\u201366","DOI":"10.21873\/invivo.13836","article-title":"Evaluation of times-to-onset and outcomes of lung adverse events associated with sorafenib using JADER","volume":"39","author":"Kanbayashi","year":"2025","journal-title":"Vivo"},{"key":"R42-20260512","first-page":"812","article-title":"Haematoma following thyroid surgery, reducing the incidence in the face of anticoagulant and antiplatelet use","volume":"116","author":"O\u2019Keeffe","year":"2023","journal-title":"Ir Med J"},{"key":"R43-20260512","doi-asserted-by":"crossref","first-page":"e22768","DOI":"10.1096\/fj.202201321RR","article-title":"Fatty acid oxidation fuels agonist-induced platelet activation and thrombus formation: targeting \u03b2-oxidation of fatty acids as an effective anti-platelet strategy","volume":"37","author":"Kulkarni","year":"2023","journal-title":"FASEB J"},{"key":"R44-20260512","doi-asserted-by":"crossref","first-page":"e70155","DOI":"10.1096\/fj.202400863RR","article-title":"Hemin promotes platelet activation and plasma membrane disintegration regulated by the subtilisin-like proprotein convertase furin","volume":"38","author":"Schaale","year":"2024","journal-title":"FASEB J"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000003667","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:26:45Z","timestamp":1778581605000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000003667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000003667","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"2025-04-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}